Semax Safety Questions: What Studies Report

What this page covers

People searching for Semax safety information usually ask two things: whether adverse effects have been documented, and whether specific concerns such as hair loss appear anywhere in the literature. This page summarises what the verified published papers stated, organised by organ system and model, and marks plainly where no published data exist. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question. Nothing here is a protocol, a dosing suggestion, or a prediction of what would happen in a person.

One framing point matters before the findings. The verified studies below were almost entirely animal experiments designed to test efficacy or mechanism in injury and behaviour models, not dedicated toxicology programmes. Researchers measured brain chemistry, gene transcription, behaviour, blood coagulation or liver histology because those endpoints answered their mechanistic question. The absence of a reported harm in an efficacy paper is therefore not evidence that the harm does not occur; it usually means the outcome was never measured.

Hair loss and Semax: What Studies Report

None of the verified studies examined hair, hair follicles, skin, or pigmentation. Searches for "Semax and hair loss" are common, but the published work summarised here reported brain, behavioural, coagulation and liver endpoints only. There is no verified study in this set that reported alopecia, shedding, hair thinning, or hair regrowth in any species, and no human trial in this set reported dermatological outcomes of any kind.

The compound itself was described across these papers as a synthetic analogue of the adrenocorticotropic hormone fragment ACTH(4-10), studied as a nootropic and neuroprotective agent. The 2005 paper reported that this ACTH(4-10) analogue activated dopaminergic and serotoninergic brain systems in rodents (PMID 16362768), and a 2021 study described Semax in the same structural terms while studying behaviour and neurochemistry in white rats (PMID 33418449). Neither study, and none of the others reviewed here, assessed melanocortin-related effects on skin or hair. Any claim that the peptide causes or prevents hair loss is unsupported by the literature summarised on this page, in either direction.

Blood clotting and platelets: What Studies Report

The most directly safety-relevant paper in this set concerned haemostasis. A 2010 study examined anticoagulation and antiplatelet effects of Semax under conditions of acute and chronic immobilisation stress, and researchers reported anticoagulant and antiplatelet activity in that stress model (PMID 21113455). The study framed these as pharmacological effects on clotting and platelet function rather than as adverse events, and it did not report bleeding episodes, surgical outcomes, or interactions with anticoagulant drugs.

What the study did not cover is as important as what it did. It was an animal experiment under experimental stress conditions; no human coagulation trial appears in this verified set, and no paper here examined people already taking antiplatelet or anticoagulant medication. Questions about bleeding risk in humans therefore have no published answer in this literature.

Liver and hepatocytes: What Studies Report

A 2017 study titled "Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress" examined liver cell structure and function in animals exposed to chronic emotional and painful stress (PMID 28577097). The study reported on the morphofunctional state of hepatocytes under those stress conditions, making it the only paper in this verified set to address a peripheral organ histologically.

No verified study reported liver enzyme panels in humans, and none examined kidney, cardiac, endocrine or reproductive tissue. Readers looking for hepatotoxicity or nephrotoxicity data will not find them in this literature set.

Dopamine and serotonin systems: What Studies Report

Neurochemical activation is relevant to safety questions because monoamine systems influence mood, sleep and appetite. Researchers reported in 2005 that the ACTH(4-10) analogue activated dopaminergic and serotoninergic brain systems in rodents, and the paper characterised those effects as underlying its nootropic properties (PMID 16362768). The study described system activation; it did not report psychiatric adverse events, dependence, tolerance, or withdrawal.

A separate 2017 study reported that Semax and Selank affected the behaviour of rats with 6-OHDA-induced parkinsonism, a model that depletes dopaminergic neurons (PMID 28702721). Behavioural change in a lesion model is not the same as a safety signal, and the paper did not report adverse behavioural outcomes in healthy animals.

Opioid receptor signalling: What Studies Report

A 2025 study reported that Semax targeted the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice (PMID 40692165). This is the paper most often raised in discussions of whether the peptide interacts with opioid pathways. The study reported a molecular mechanism and functional recovery in an injury model; it did not report analgesic tolerance, respiratory effects, dependence, or interaction with opioid medications.

Two limitations were stated in the study description itself: the work used mice, and it used female animals. Whether the same receptor-level findings extend to males, to other species, or to intact uninjured nervous systems was not addressed by that paper.

Brain network-level effects: What Studies Report

A 2020 paper applied a functional connectomic approach to studying Selank and Semax effects, examining changes at the level of brain network connectivity rather than single regions (PMID 32342318). The study reported connectivity-level effects; it did not present adverse neurological findings, seizure data, or long-term follow-up.

Early-life exposure and developmental models: What Studies Report

The closest the verified set comes to a developmental question is a 2021 study reporting that Semax attenuated behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats (PMID 33418449). The study's design tested whether the peptide corrected alterations produced by an antidepressant given early in life; it was not a reproductive or developmental toxicology study, and it did not report on pregnancy, lactation, or growth outcomes.

No verified study examined use in children, in pregnancy, or in nursing animals as a safety endpoint. Those populations have no published data in this set.

Neurological injury and disease models: What Studies Report

Most of the remaining literature examined efficacy in damage models, and each paper reported outcomes rather than toxicity. A 2006 study reported neuroprotective and antiamnesic effects during experimental ischaemic infarction of the cerebral cortex (PMID 17603664). A 2010 paper reported that Semax and Pro-Gly-Pro activated transcription of neurotrophins and their receptor genes after cerebral ischaemia (PMID 19633950), and a 2020 transcriptome study reported protective properties of ACTH(4-7)PGP following cerebral ischaemia–reperfusion in rats (PMID 32580520).

A 2016 study reported that Semax prevented learning and memory inhibition caused by heavy metals in an animal model (PMID 27411820), and a 2025 paper examined the potential of Semax and a derivative for correcting pathological impairments in an animal model of Alzheimer's disease (PMID 41479572). None of these reported mortality, organ toxicity, or dose-limiting effects as a stated outcome; none were designed to detect them.

Study-by-study overview

Populations with no published data: What Studies Report

Across the verified set, several groups were never studied as a safety population. There were no reported data on pregnancy or breastfeeding, no paediatric data, no data in older adults, no data in people with hepatic or renal impairment, and no data in people taking anticoagulants, antiplatelet drugs, opioids, antidepressants or dopaminergic medication. The one paper touching opioid pathways studied female mice after spinal cord injury (PMID 40692165), and the one paper touching antidepressant exposure studied rats given fluvoxamine early in life (PMID 33418449). Neither addressed concurrent medication use in humans.

Gaps in the safety literature: What Studies Report

Several categories of safety information that people commonly look for are simply absent from these papers:

• Dermatological outcomes. No verified study reported hair, skin or pigmentation endpoints.
• Long-term exposure. No verified study reported multi-month or lifetime follow-up, carcinogenicity, or organ accumulation.
• Human adverse-event tables. No verified study in this set was a controlled human trial reporting treatment-emergent adverse events.
• Withdrawal and dependence. Although one study reported dopaminergic and serotoninergic activation in rodents (PMID 16362768), no verified study assessed tolerance, dependence or discontinuation effects.
• Endocrine effects. Despite the peptide's description as an ACTH fragment analogue, no verified study reported cortisol, adrenal or other hormonal safety measures.

Regulatory context

Semax is not an approved drug product in the United States and is not sold as an approved medicine there; peptide material of this kind is commonly labelled research use only. Regulatory status differs between countries and changes over time. This page does not discuss sourcing, availability or legality in any jurisdiction, and it is not legal advice.

How the evidence should be read

Taken together, the verified literature described a peptide studied mainly for neuroprotection, cognition and recovery after neural injury, with a small number of papers touching haemostasis and liver histology. The strongest safety-adjacent finding was the report of anticoagulant and antiplatelet activity in a stress model (PMID 21113455), and the only peripheral organ study concerned hepatocytes under chronic stress (PMID 28577097). Everything else described efficacy or mechanism in disease models. For the specific question of hair loss, the answer from this literature is that the outcome has not been studied and no finding exists to report. Individual health decisions belong with a licensed physician who can review a person's full medical history.

References

• Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice (British Journal of Pharmacology, 2025)
• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats (Neuropeptides, 2021)
• The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease (Acta Naturae, 2025)
• Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress (Bulletin of Experimental Biology and Medicine, 2017)
• Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia (Cellular and Molecular Neurobiology, 2010)
• Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilization stress (Bulletin of Experimental Biology and Medicine, 2010)
• Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex (Bulletin of Experimental Biology and Medicine, 2006)
• Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism (Doklady Biological Sciences, 2017)
• Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats (Genes, 2020)
• Semax prevents learning and memory inhibition by heavy metals (Doklady Biological Sciences, 2016)
• Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents (Neurochemical Research, 2005)